

Prof. Dr. Serge Mignani

Serge Mignani obtained a “diplôme d'ingénieur” degree in 1977 from the ‘Ecole Nationale Supérieure de Chimie de Rennes’ (University of Rennes, France). In 1978, he joined the Catholic University of Louvain-la-Neuve (Belgium) for a Ph.D. training under the supervision of Prof H. G. Viehe (two thesis). Then, he joined the University of Madison (USA) for a postdoctoral stay under the supervision of Prof B. M. Trost. In 1981, he joined Rhône-Poulenc (currently Sanofi) at the Vitry Research Center (France), where he was Head of the Medicinal Chemistry Department and Scientific Director.

His research interests included medicinal chemistry, organic synthesis, nanotechnologies, drug delivery and vectorisation approaches. His research team has been involved successively in the preparation of new anti-convulsive, anxiolytic, anti-depressive, anti-ischaemic, anti- HIV, anti-diabetic, anti-bacterial and anti-tumour agents with original mechanism of action. More than ten clinical candidates have been disclosed by his teams. Serge Mignani is author of more 160 publications and more 100 patents. More than 70 invited plenary lectures and conferences have been presented.

He was member of the “Comité National de la Chimie”, Vice- President of the “French- Japanese Society for Fine and Medicinal Chemistry”, and he was nominated National Representative from France to the IUPAC Division of Chemistry and Human Health

S. Mignani is consultant for several medium pharmaceutical industries (Canada and USA) and Institutes (France, China, Portugal, Poland, and India) and provides training courses in ‘Modern’ Medicinal Chemistry at several universities (France, Spain, China, Belgium, India, Portugal, Chile and Morocco).

S. Mignani is associated researcher and advisor at the University Paris Descartes, Faculté des Sciences Fondamentales et Biomédicales, UMR 8601 (University of Medicine)

S. Mignani is Consultant to President at Glycovax Pharma (Montreal, Canada) (2017-) and SAPIR Pharmaceuticals (USA) (2019 -)

S. Mignani has been nominated in 2018 as Advisory Professor in the Donghua University (Shanghai, China)

Founder member of the Sino-French Network on Theranostics and Medicinal Chemistry (SF-NTMC), and scientific advisor (2018 -). Others funders: Prof. X. Shi (Donghua university, China) and Prof. J-P. Majoral (LCC, Toulouse, France)

He started strong collaborations in medicinal chemistry and nanomedicine in several therapeutic areas such as cancer, tuberculosis, body infections, CNS degenerative diseases, inflammation, blood disorders, and imaging researches with the Indian Institute of Integrative Medicine (Dr Ram Vishwakarma, IIM, preclinical candidates and one compound in clinical phase in the oncology domain) at Jammu, India, with the ‘Laboratoire Chimie de Coordination’ (Dr. Jean-Pierre Majoral, LCC, preclinical candidates in oncology and tuberculosis domain, and new therapeutic phosphorus dendrimers development) at Toulouse, France, with the Donghua University (Prof. X. Shi, new phosphorus dendrimers in the theranostic field) at Shanghai, China, with the CDRI at Lucknow, India (Prof. K. K. Srivastava and Prof. R.P. Tripathi, preclinical candidates in oncology and tuberculosis domains), and with the Centro de Quimica da Madeira, University of Madeira (nanomedicine and drug discovery, Prof. Joao Rodrigues) at Fungal, Portugal.

Recently, he was nominated Full Professor at the Centro de Quimica da Madeira, University of Madeira at Fungal, Portugal, and Guest Editors (2017 -): China Science Materials and Pharmaceutics